Thor Medical 
Welcome,         Profile    Billing    Logout  
 1 Product   3 Diseases  1 Product   1 Trial   170 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Betalutin (177Lu-satetraxetan-lilotomab) / Thor Medical
PARADIGME, NCT01796171 / 2011-000033-36: A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

Hourglass Jul 2018 - Dec 2018 : Completion of enrollment in pivotal P2 PARADIGME trial
Checkmark LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Nov 2018 - Nov 2018: LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Hourglass Oct 2016 - Dec 2016 : SRC review of data from arms 3 and 4 of P1/2 Lymrit 37-01 trial for FL
Hourglass Oct 2016 - Dec 2016 : Dose escalation in arm 1 and either arm 3 or 4 of P1/2 Lymrit 37-01 trial for FL
More
Completed
1/2
191
Europe, Canada, US, RoW
10 MBq/kg Betalutin, 15 MBq/kg Betalutin, 20 MBq/kg Betalutin, 40 mg lilotomab, 100 mg/m2 lilotomab, 60 mg/m2 lilotomab, Rituximab, 12.5 mBq/kg Betalutin
Nordic Nanovector, ICON Clinical Research
Non-Hodgkin Lymphoma, Follicular Lymphoma
10/22
10/22
Humalutin (177Lu-DOTA-NNV003) / Thor Medical
No trials found
NNV009 / Thor Medical
No trials found
NNV011 / Thor Medical
No trials found
NNV013 / Thor Medical, Orano
No trials found
Alpha 37 / Thor Medical, Orano
No trials found
CD37 DOTA CAR-T / Thor Medical
No trials found
NNV024 / Thor Medical
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Betalutin (177Lu-satetraxetan-lilotomab) / Thor Medical
PARADIGME, NCT01796171 / 2011-000033-36: A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

Hourglass Jul 2018 - Dec 2018 : Completion of enrollment in pivotal P2 PARADIGME trial
Checkmark LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Nov 2018 - Nov 2018: LYMRIT 37-01 data for r/r indolent NHL at ASH 2018
Hourglass Oct 2016 - Dec 2016 : SRC review of data from arms 3 and 4 of P1/2 Lymrit 37-01 trial for FL
Hourglass Oct 2016 - Dec 2016 : Dose escalation in arm 1 and either arm 3 or 4 of P1/2 Lymrit 37-01 trial for FL
More
Completed
1/2
191
Europe, Canada, US, RoW
10 MBq/kg Betalutin, 15 MBq/kg Betalutin, 20 MBq/kg Betalutin, 40 mg lilotomab, 100 mg/m2 lilotomab, 60 mg/m2 lilotomab, Rituximab, 12.5 mBq/kg Betalutin
Nordic Nanovector, ICON Clinical Research
Non-Hodgkin Lymphoma, Follicular Lymphoma
10/22
10/22
Humalutin (177Lu-DOTA-NNV003) / Thor Medical
No trials found
NNV009 / Thor Medical
No trials found
NNV011 / Thor Medical
No trials found
NNV013 / Thor Medical, Orano
No trials found
Alpha 37 / Thor Medical, Orano
No trials found
CD37 DOTA CAR-T / Thor Medical
No trials found
NNV024 / Thor Medical
No trials found

Download Options